申请人:Bayer Aktiengesellschaft
公开号:US06362178B1
公开(公告)日:2002-03-26
The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
具有短的、非支链烷基基团的2-苯基取代咪唑三嗪酮在9位制备自相应的2-苯基咪唑三嗪酮,通过氯磺化和随后与胺反应。这些化合物抑制cGMP代谢磷酸二酯酶,适用于作为药物中的活性化合物,用于治疗心血管和脑血管疾病和/或泌尿系统疾病,特别是治疗勃起功能障碍。